Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 02, 2024 | Director, President and CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 8,333 | -- | 91,667 | |
| Jun 27, 2007 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4/A | 5,700 | $11.25 | 91,612 | |
| Jun 27, 2007 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 5,700 | $11.25 | 91,612 | |
| Jan 02, 2020 | Chief People Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 91,439 | -- | 91,439 | |
| Sep 11, 2019 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | -- | 91,439 | |
| Jul 13, 2015 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 7,750 | $15.01 | 91,249 | |
| Aug 05, 2021 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 22,000 | -- | 90,935 | |
| May 14, 2018 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | $2.29 | 90,409 | |
| Apr 12, 2018 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | $2.29 | 90,409 | |
| Mar 12, 2018 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | $2.29 | 90,409 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.